1,1000 0,01 (0,92 %)
Nachbörse: 7:59PM EST
|Dr. Geraldine A. Henwood||Pres, CEO & Director||48,37k||N/A||1952|
|Mr. Ryan D. Lake||CFO & Treasurer||29,44k||N/A||1977|
|Dr. Stewart McCallum||Chief Medical Officer||N/A||N/A||1966|
|Mr. John Harlow||Chief Commercial Officer||N/A||N/A||1976|
|Mr. Randall J. Mack||Sr. VP of Devel.||N/A||N/A||1965|
|Ms. Diane Myers||Sr. VP of Regulatory & Quality||N/A||N/A||1964|
|Dr. Jyrki Mattila||Exec. VP of Bus. Devel.||N/A||N/A||1955|
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Baudax Bio, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.